Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753674 · ClinicalTrials.gov registry record · Phase 1
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
A Phase 1 study, sponsored by University of Connecticut.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01753674: Clinical Trial Phase 1 study, sponsored by University of Connecticut.
NCT01753674 is a Phase 1 study that was terminated before completion, run by University of Connecticut. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753674, a Phase 1 study, was terminated before completion, sponsored by University of Connecticut.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.
Primary Outcome
The supplement is anticipated to decrease insulin resistance in individuals with metabolic syndrome. The investigators will measure plasma insulin and plasma glucose as outcomes measures
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT TA-65
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Why NCT01753674 stopped before completion
NCT01753674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01753674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01753674 about?
NCT01753674 is a clinical study titled "The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome". Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.
What is the current status of trial NCT01753674?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01753674?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), TA-65 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01753674?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01753674's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia